The grant provides modest non-dilutive capital and validates BioHarvest's technology platform, but does not change near-term revenue or profitability outlook. Monitor for progress on commercial milestones that would trigger repayment and for any future CDMO customer contracts that could benefit from the accelerated R&D.
Price Chart
Executive Summary
BioHarvest Sciences announced a $1.4M non-dilutive grant from the Israel Innovation Authority to fund an AI-driven R&D initiative for plant-cell synthesis. The grant is a zero-interest loan repayable only from future project revenues and strengthens the company's financial position without dilution.
Key Facts
- IIA approved a 4.33M NIS (~$1.4M USD) non-dilutive grant for AI-driven plant-cell synthesis R&D
- Grant is a zero-interest loan; repayment contingent on commercial milestones from future project revenues
- No equity or equity-linked instruments were issued in connection with the grant
- This is the second IIA grant BioHarvest received in 2026; the first was for manufacturing automation
- Grant will fund integration of data science, ML, computer vision, and high-throughput digital sensing into biological development workflows
Financial Impact
$1.4M non-dilutive grant with contingent repayment from future project revenues
Risk Factors
- Grant is a loan repayable from future project revenues; no assurance those revenues will materialize
- Forward-looking statements caution that increased revenue does not guarantee net income or profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001723464-26-000036 |
| Document: bhsc_ex991.htm | 0001723464-26-000036 |
| Document: 0001723464-26-000036-index-headers.html | 0001723464-26-000036 |
| Document: 0001723464-26-000036-index.html | 0001723464-26-000036 |
| Document: 0001723464-26-000036.txt | 0001723464-26-000036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.75 $1.67 | ▼ −4.18% | ▼ −4.64% | $1.68 (−3.72%) |
Oct 8, 2026 18d ago | 6-K | $1.50 $1.70 | ▲ +13.71% | ▲ +13.99% | $1.68 (+12.37%) |
Sep 15, 2026 5w ago | 6-K | $1.66 $1.46 | ▼ −12.05% | ▼ −14.61% | $1.68 (+1.20%) |
Sep 14, 2026 6w ago | 6-K | $1.78 $1.51 | ▼ −14.93% | ▼ −17.04% | $1.68 (−5.35%) |
Jul 15, 2026 14w ago | 6-K | $2.85 $2.18 | ▼ −23.51% | ▼ −22.53% | $1.68 (−41.05%) |
Jun 18, 2026 18w ago | 6-K | $3.26 $2.75 | ▼ −15.64% | ▼ −13.98% | $1.68 (−48.47%) |
May 28, 2026 21w ago | 6-K | $3.90 $3.56 | ▼ −8.72% | ▼ −8.67% | $1.68 (−56.92%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.68 (−59.62%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▲ +8.17% | ▲ +7.46% | $1.68 (+59.62%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.68 (−59.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers